# Induction of Remission in RA Patients at Low Disease Activity by Additional Infliximab Therapy (Study P04644AM1) (TERMINATED)

> **NCT00521924** · PHASE3 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 8 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** infliximab
- **DRUG:** DMARDs (methotrexate; chloroquine; leflunomidum; cyclosporin A; sulfasalazine; OM 89.

## Key facts

- **NCT ID:** NCT00521924
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-06
- **Primary completion:** 2008-04
- **Final completion:** 2008-04
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Slow Enrollment
- **Last updated:** 2017-04-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00521924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00521924, "Induction of Remission in RA Patients at Low Disease Activity by Additional Infliximab Therapy (Study P04644AM1) (TERMINATED)". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00521924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*